SOLID DOSAGE FORM DEVELOPMENT OF GLIBENCLAMIDE-ASPARTAME COCRYSTAL USING THE SOLVENT EVAPORATION METHOD TO INCREASE THE SOLUBILITY OF GLIBENCLAMIDE

  • ARIF BUDIMAN Department of Pharmaceutical and Technology Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran,
  • SANDRA MEGANTARA Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran,
  • AYU APRILIANI Department of Pharmaceutical and Technology Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran,

Abstract

Objective: The solubility of a drug in water plays an important role in the absorption of the drug after oral administration. Cocrystal is one method that improves the solubility of the active pharmaceutical ingredient (API). The aim of this study was to investigate the formation of a glibenclamide (GCM)-aspartame (APM) cocrystal using the solvent evaporation method and to evaluate its solubility and dissolution rate.


Methods: Molecular docking of the GCM-APM cocrystal was observed using an in silico method. The GCM-APM cocrystal (1:2) was prepared by using the solvent evaporation method. The cocrystal of GCM-APM was evaluated by the saturated solubility test and the dissolution rate test (USP type 2 apparatus). The solvent evaporation product of GCM-APM was characterized by Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), and powder X-ray diffraction (PXRD).


Results: In silico study showed that the interaction of GCM-APM has hydrogen bonding and the potential to improve the solubility of GCM. Evaluation of the cocrystal of GCM-APM showed that the solubility and dissolution rate of the cocrystal are significantly increased. Characterization of FT-IR showed that no chemical reaction occurred in the GCM-APM cocrystal. The DSC analysis showed the changes in the melting point of GCM. Measurement of PXRD showed the formation of a new solid crystal phase that is different from GCM and APM.


Conclusion: GCM-APM has hydrogen bonding can improve the solubility and dissolution rate of GCM.

Keywords: Cocrystal, Glibenclamide, Aspartame, Solvent Evaporation

References

1. Hu J, Johnston KP, Williams RO. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm 2004;30:233-45.
2. Khadka P, Ro J, Kim H. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci 2014;9:304-16.
3. Silva Filho SF, Pereira AC, Sarraguça JMG. Synthesis of a glibenclamide cocrystal: full spectroscopic and thermal characterization. J Pharm Sci 2018;107:1597-604.
4. Tabbakhian M, Hasanzadeh F, Tavakoli N, Jamshidian Z. Dissolution enhancement of glibenclamide by solid dispersion: Solvent evaporation versus a supercritical fluid-based solvent-antisolvent technique. Res Pharm Sci 2014;9:337-50.
5. Dora CP, Singh SK, Kumar S, Datusalia AK, Deep A. Development and characterization of nanoparticles of glibenclamide by solvent displacement method. Acta Pol Pharm Drug Res 2010;67:283-90.
6. Bari A, Chella N, Sanka K, Shastri NR, Diwan PV. Improved anti-diabetic activity of glibenclamide using oral self nano emulsifying powder. J Microencapsul 2015;32:54-60.
7. Fukte SR, Wagh MP, Rawat S. Coformer selection: an important tool in cocrystal formation. Int J Pharm Pharm Sci 2014;6:9-14.
8. Purwantoro DU, Nugrahani I, Surantaatmadja SI. Studies of preparation, characterization, and solubility of mefenamic acid-nicotinamide co-crystal synthesized by using a melt crystallization method. Asian J Pharm Clin Res 2017;10:135-9.
9. Sopyan I, Fudholi A, Muchtaridi M, Sari I. Co-crystallization: a tool to enhance solubility and dissolution rate of simvastatin. J Young Pharm 2017;9:183-6.
10. Budiman A, Nurlatifah E, Amin S. Enhancement of solubility and dissolution rate of glibenclamide by cocrystal approach with solvent drop grinding method. Int J Curr Pharm Rev Res 2016;7:248-50.
11. Gozali D, Megantara S, Levita J, Bahti HH, Soewandhi SN, Abdassah M. Virtual screening of coformers for atorvastatin co-crystallization and the characterizations of the co-crystals. Int J Pharm Sci Res 2016;7:1450-5.
12. Siswandi S, Rusdiana T, Levita J. Virtual screening of co-formers for ketoprofen co-crystallization and the molecular properties of the co-crystal. J Appl Pharm Sci 2015;5:78-82.
13. Setyawan D, Sari R, Yusuf H, Primaharinastiti R. Preparation and characterization of artesunate-nicotinamide cocrystal by solvent evaporation and slurry method. Asian J Pharm Clin Res 2014;7:62-5.
14. Gianotto EADS, Arantes RP, Lara-Filho MJ, Casimiro Filho ACS, Fregonezi-Nery MM. Dissolution test for glibenclamide tablets. Quim Nova 2007;30:1218-21.
15. Lobenberg R, Kramer J, Shah VP, Amidon GL, Dressman JB. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res 2000;17:439-44.
16. Vinesha V, Sevukarajan M, Rajalakshmi R, Chowdary GT, Haritha K. Enhancement of solubility of tadalafil by cocrystal approach. Int Res J Pharm 2016;4:218-23.
17. Goyal P, Rani D, Chadha R. Crystal engineering: a remedy to tailor the biopharmaceutical aspects of glibenclamide. Cryst Growth Des 2018;18:105-18.
18. Pathak CD, Savjani KT, Gajjar AK, Savjani JK. Cocrystal formation of paracetamol with indomethacin and mefenamic acid: an efficient approach to enhance solubility. Int J Pharm Pharm Sci 2013;5:414-9.
19. Budiman A, Khoerunnisa R, Qoriah T. Wound-healing test of piper betle leaf extract and aloe vera in gel preparation. Int J Appl Pharm 2018;10:86-91.
20. Trask AV, Motherwell WDS, Jones W. Physical stability enhancement of theophylline via cocrystallization. Int J Pharm 2006;320:114-23.
21. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: an overview. Int J Pharm 2011;419:1-11.
22. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodriguez Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm 2013;453:101-25.
23. Shete A, Murthy S, Korpale S, Yadav A, Sajane S, Sakhare S, et al. Cocrystals of itraconazole with amino acids: Screening, synthesis, solid-state characterization, in vitro drug release and antifungal activity. J Drug Delivery Sci Technol 2015;28:46-55.
24. Huang X, Lai Y, Hang ZH, Zheng H, Chan CT. Dirac cones induced by accidental degeneracy in photonic crystals and zero-refractive-index materials. Nat Mater 2011;10:582-6.
25. Prohens R, Puigjaner Vallet MC. Crystal engineering studies: polymorphs and co-crystals. Handb Instrum Tech from CCiTUB; 2012. p. 45-124.
26. Musumeci D, Hunter CA, Prohens R, Scuderi S, McCabe JF. Virtual cocrystal screening. Chem Sci 2011;2:883-90.
27. Budiman A, Megantarab S, Raraswati P, Tazyinul Qoriah A. Solid dosage form development of glibenclamide with increasing the solubility and dissolution rate using cocrystallization. Int J Appl Pharm 2018;10:181-6.
Statistics
39 Views | 23 Downloads
How to Cite
BUDIMAN, A., MEGANTARA, S., & APRILIANI, A. (2019). SOLID DOSAGE FORM DEVELOPMENT OF GLIBENCLAMIDE-ASPARTAME COCRYSTAL USING THE SOLVENT EVAPORATION METHOD TO INCREASE THE SOLUBILITY OF GLIBENCLAMIDE. International Journal of Applied Pharmaceutics, 11(3), 150-154. https://doi.org/10.22159/ijap.2019v11i3.32121
Section
Original Article(s)